INOVIO PHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $81.62M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | After market close | – | $-0.07 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | After market close | – | $-0.28 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | After market close | – | $-0.26 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | After market close | – | $-0.87 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | – | $-0.61 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | – | $-0.51 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 18, 2025 | After market close | – | $-0.65 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | – | $-0.89 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 12, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| operational net cash burn | third quarter of 2026 | $18.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Inovio Pharmaceuticals filed with the SEC
INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
INOVIO Announces Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
INOVIO Announces Pricing of $20.0 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
INOVIO Announces Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
INOVIO Announces Pricing of $17.5 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
FDA Accepts for Review INOVIO’s BLA for INO-3107 for the Treatment
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
INOVIO Announces Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
INOVIO Announces Pricing of $25 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
INOVIO Announces Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
INOVIO Announces Pricing of $25 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Results of operations · EX-99.1 to Form 8-K
INOVIO Announces Pricing of $30 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and
Material agreement · Other events · EX-99.1 to Form 8-K
INOVIO Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update
Results of operations · EX-99.1 to Form 8-K
STIPULATION AND AGREEMENT OF SETTLEMENT
Regulation FD disclosure · EX-99.1 to Form 8-K
INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
Regulation FD disclosure · EX-99.2 to Form 8-K
INOVIO Reports First Quarter 2023
Results of operations · EX-99.1 to Form 8-K
INOVIO Reports Fourth Quarter and Full Year 2022 Financial
Results of operations · EX-99.1 to Form 8-K
Continues Efforts to Focus on Promising DNA Medicine Candidates
Exit or restructuring costs · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
INOVIO Reports Financial Results and Highlights for the Third Quarter 2022
Results of operations · EX-99.1 to Form 8-K
INOVIO Reports Financial Results and Highlights for the Second Quarter 2022
Results of operations · EX-99.1 to Form 8-K
INOVIO Announces Corporate Reorganization to Reduce Operational Expenses and Focus on Opportunities to
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
INOVIO Reports First Quarter 2022 Financial Results
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K